E T Papoutsakis
Overview
Explore the profile of E T Papoutsakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
1907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindsey S, Jiang J, Woulfe D, Papoutsakis E
J Thromb Haemost
. 2014 Jan;
12(3):383-94.
PMID: 24410994
Background: We previously identified aryl hydrocarbon receptor (AHR) as a novel regulator of megakaryocytic differentiation and polyploidization and reported that AHR-null mice have approximately 15% fewer platelets than do wild-type...
2.
McAdams T, Sandstrom C, Miller W, Bender J, Papoutsakis E
Cytotechnology
. 2012 Feb;
18(1-2):133-46.
PMID: 22358646
Sources of hematopoietic cells for bone marrow transplantation are limited by the supply of compatible donors, the possibility of viral infection, and autologous (patient) marrow that is depleted from prior...
3.
Collins P, Patel S, Miller W, Papoutsakis E
Methods Mol Med
. 2011 Mar;
18:271-92.
PMID: 21370184
The culture of hematopoietic cells for cell and gene therapies is a rapidly growing area within the field of applied hematology and tissue engineering. As evidenced by recent clinical trials...
4.
Collins P, Patel S, Papoutsakis E, Miller W
Cytotherapy
. 2009 Sep;
1(2):99-109.
PMID: 19746586
Background: Current protocols for transplantation of hematopoietic stem and progenitor cells may be limited by donor-cell availability and the long time needed to restore neutrophil and platelet counts to normal...
5.
Nielsen L, Bender J, Miller W, Papoutsakis E
Cytotechnology
. 2008 Nov;
28(1-3):157-62.
PMID: 19003417
In this paper, we develop a simple four parameter population balance model of in vivo neutrophil formation following bone marrow rescue therapy. The model is used to predict the number...
6.
Guo M, Miller W, Papoutsakis E, Patel S, James C, Goolsby C, et al.
Cytotherapy
. 2003 Jul;
1(3):183-94.
PMID: 12881174
Background: Previous ex-vivo expansion studies in our laboratory, comparing unselected and CD34(+)-selected PBMC, have shown no advantage for CD34(+) cell selection, in terms of the expansion achieved. Our goal was...
7.
Yang H, Miller W, Papoutsakis E
Stem Cells
. 2002 Jul;
20(4):320-8.
PMID: 12110701
Megakaryocytic (Mk) cells mature adjacent to bone marrow (BM) sinus walls and subsequently release platelets within the sinusoidal space or in lung capillaries. In contrast, primitive stem and Mk progenitor...
8.
Carswell K, Weiss J, Papoutsakis E
Cytotherapy
. 2002 Jun;
2(1):25-37.
PMID: 12042052
Background: Optimization of the culture environment for the ex vivo expansion of T cells is crucial for obtaining the large doses of cells needed for cellular immunotherapy. O2 tension is...
9.
Patel S, Guo R, Miller W, Papoutsakis E, Minster N, Baum C, et al.
Cytotherapy
. 2002 Jun;
2(2):85-94.
PMID: 12042045
Background: Supplementation of PBPC autografts with ex vivo expanded PBMC may significantly reduce or eliminate the period of neutropenia associated with high-dose chemotherapy. Methods: Unmanipulated growth-factor mobilized PBMC were expanded...
10.
Patel S, Miller W, Winter J, Papoutsakis E
Cytotherapy
. 2002 Jun;
2(4):267-80.
PMID: 12042036
Background: Our goal was to produce granulocyte progenitor (CFU-G) and post-progenitor (CD15(+)CD11b(+/-)) cells for subsequent transplantation. We hypothesized that increasing the feeding frequency and maintaining constant densities may overcome inhibitory...